Lipoprotein(a): The Cardiovascular Risk Marker Many People Have Never Been Told About

HormoneSynergy®
Preventive Longevity Medicine
HormoneSynergy® Clinic — Portland & Lake Oswego, Oregon | USA

Lp(a) Is Not Just Another Cholesterol Number

Lipoprotein(a) is an LDL-like particle with an added protein called apolipoprotein(a). That structure matters. Lp(a) can contribute to plaque formation, inflammation, and clotting activity inside the vascular system.

For many patients, Lp(a) is the missing piece. Their standard cholesterol panel may look only mildly abnormal, or even fairly reasonable, while their inherited cardiovascular risk is higher than expected.

This is one reason Dr. Retzler often evaluates Lp(a) alongside apoB, LDL particle burden, hs-CRP, insulin resistance, blood pressure, family history, vascular imaging, hormone status, kidney function, thyroid function, and metabolic health. One number matters. The whole risk pattern matters more.

Common Lp(a) Ranges

Lp(a) can be reported in two different units: mg/dL or nmol/L. These are not directly interchangeable. A simple conversion is not reliable because Lp(a) particle size varies between people.

In general, the American Heart Association and American College of Cardiology recognize Lp(a) at or above 50 mg/dL or 125 nmol/L as elevated cardiovascular risk.

So when someone says, “My Lp(a) is 200,” the first question is simple: 200 in what units?

An Lp(a) of 200 nmol/L is clearly elevated and near the very high-risk range. An Lp(a) of 200 mg/dL is an extreme elevation and should be taken very seriously in a medical setting.

Why Elevated Lp(a) Matters

High Lp(a) is associated with a higher lifetime risk of cardiovascular disease. That includes heart attack, ischemic stroke, coronary artery disease, peripheral artery disease, and calcific aortic valve stenosis.

It is also mostly genetic. Lifestyle habits do not usually lower Lp(a) in a meaningful way. That does not make lifestyle irrelevant. It means lifestyle is not the direct treatment for the Lp(a) number itself.

The clinical strategy is to reduce everything else that adds fuel to the same fire: apoB, LDL-C, blood pressure, insulin resistance, smoking, inflammatory burden, poor sleep, visceral fat, sedentary behavior, and untreated metabolic disease.

How Lp(a) Is Approached Clinically

At HormoneSynergy®, elevated Lp(a) is not treated as a wellness trend. It is treated as a cardiovascular risk marker that deserves proper context.

Clinical next steps may include:

• Confirming the Lp(a) units and whether the test was done during a stable health period.
• Measuring apoB, LDL-C, LDL particle burden, HDL, triglycerides, hs-CRP, fasting insulin, A1c, kidney function, thyroid function, and other relevant markers.
• Reviewing personal and family history of early heart disease, stroke, valve disease, or unexplained cardiovascular events.
• Considering vascular imaging, such as CIMT, coronary calcium scoring, or coronary CT angiography when clinically appropriate.
• Discussing LDL-C and apoB lowering targets with the patient’s physician.
• Screening first-degree relatives, because Lp(a) is often inherited.

When Lp(a) is elevated, LDL-C, ApoB, LDL particle burden, and blood pressure become even more important. These are not side issues. They are part of the risk environment around Lp(a). Because Lp(a) is mostly inherited and not easily changed through lifestyle, the clinical strategy is often to lower the modifiable risks around it as intelligently and aggressively as the patient’s overall risk profile warrants.

What About Soft Plaque?

Lp(a) can raise concern about plaque that may not be fully captured by a standard cholesterol panel. Coronary artery calcium scoring can identify calcified plaque, but it does not directly show non-calcified or “soft” plaque.

For patients specifically asking whether soft plaque is present in the coronary arteries, coronary CT angiography with advanced plaque analysis may be considered. Cleerly® is one example of AI-assisted analysis used with CCTA to assess plaque volume, composition, stenosis, and non-calcified plaque.

Imaging should be chosen based on the person, not fear. The right test depends on age, symptoms, family history, prior testing, kidney function, radiation considerations, medication status, and overall cardiovascular risk.

Medications and Lp(a)

There is currently no widely approved medication used solely to lower Lp(a) for primary prevention. That is changing quickly, with several Lp(a)-targeted therapies in clinical trials.

For now, physicians often focus on lowering apoB and LDL-C aggressively when Lp(a) is elevated. Statins lower LDL-C and cardiovascular risk, but they do not meaningfully lower Lp(a). PCSK9 inhibitors can lower LDL-C substantially and may lower Lp(a) modestly. Lipoprotein apheresis is reserved for select high-risk cases and is not a routine treatment for most patients.

The practical point is this: elevated Lp(a) should usually make the conversation about LDL-C, apoB, blood pressure, metabolic health, and plaque assessment more serious.

What Patients Should Ask Their Physician

• Was my Lp(a) measured in mg/dL or nmol/L?
• How does this change my lifetime cardiovascular risk?
• Should my apoB and LDL-C targets be lower because of this result?
• Do I need plaque imaging, and if so, which test makes the most sense?
• Should my children, siblings, or parents be screened?
• Do I have other risk factors that make this more urgent?

The HormoneSynergy® Position

Lp(a) is not a reason to panic. It is a reason to stop guessing.

If Lp(a) is elevated, especially markedly elevated, the job is to understand whether risk is theoretical, early, active, or already measurable. That means better labs, better imaging when appropriate, and a prevention plan that is specific enough to matter.

This is medicine, not marketing. A high Lp(a) result should not be used to sell fear. It should be used to sharpen clinical judgment.

Related HormoneSynergy® Resources

• HormoneSynergy® Longevity Medicine Resource Library
• Optimal Aging Assessment vs. Cleerly® Testing
• ApoB vs. LDL-C: What Actually Matters?
• LDL-C vs. LDL-P Discordance
• Blood Pressure and Longevity
• Preventive Cardiology and Longevity Medicine

References

• American Heart Association: Lipoprotein(a)
• American College of Cardiology: Update on Lipoprotein(a)
• 2026 ACC/AHA Guideline on the Management of Dyslipidemia
• Endotext: Management of Patients With Elevated Lp(a)

FAQ

Is Lp(a) genetic?

Yes. Lp(a) is largely genetically determined and tends to remain fairly stable throughout life.

Can diet or exercise lower Lp(a)?

Usually not in a meaningful way. Diet, exercise, sleep, smoking avoidance, and metabolic health still matter because they reduce overall cardiovascular risk.

What level of Lp(a) is considered high?

Lp(a) at or above 50 mg/dL or 125 nmol/L is generally considered elevated. Higher levels carry higher risk, especially when combined with other cardiovascular risk factors.

Why do LDL-C, ApoB, and blood pressure matter if Lp(a) is genetic?

Because elevated Lp(a) raises baseline cardiovascular risk, the modifiable risks around it matter even more. Lowering ApoB and LDL-C, improving blood pressure, reducing insulin resistance, and addressing inflammation can help reduce the total vascular burden even if Lp(a) itself remains elevated.

Should family members be tested?

Often, yes. Because Lp(a) is inherited, first-degree relatives may benefit from screening.

Does a high Lp(a) mean I already have plaque?

No. It means risk is higher. Imaging may help determine whether plaque is present, but the decision should be individualized with a physician.